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in pathogenic T cells, providing a mechanism 
of modulation of autoimmunity by atorvastatin
Shannon E. Dunn,1 Sawsan Youssef,1 Matthew J. Goldstein,1 
Thomas Prod’homme,2 Martin S. Weber,2 Scott S. Zamvil,2 
and Lawrence Steinman1
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305
2Department of Neurology, University of California San Francisco, CA 94143
3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase is a critical enzyme in the 
mevalonate pathway that regulates the biosynthesis of cholesterol as well as isoprenoids 
that mediate the membrane association of certain GTPases. Blockade of this enzyme by 
atorvastatin (AT) inhibits the destructive proinfl ammatory T helper cell (Th)1 response 
during experimental autoimmune encephalomyelitis and may be benefi cial in the treatment 
of multiple sclerosis and other Th1-mediated autoimmune diseases. Here we present evi-
dence linking specifi c isoprenoid intermediates of the mevalonate pathway to signaling 
pathways that regulate T cell autoimmunity. We demonstrate that the isoprenoid geranyl-
geranyl-pyrophosphate (GGPP) mediates proliferation, whereas both GGPP and its precursor, 
farnesyl-PP, regulate the Th1 differentiation of myelin-reactive T cells. Depletion of 
these isoprenoid intermediates in vivo via oral AT administration hindered these T cell 
responses by decreasing geranylgeranylated RhoA and farnesylated Ras at the plasma 
membrane. This was associated with reduced extracellular signal–regulated kinase (ERK) 
and p38 phosphorylation and DNA binding of their cotarget c-fos in response to T cell 
receptor activation. Inhibition of ERK and p38 mimicked the effects of AT and induced 
a Th2 cytokine shift. Thus, by connecting isoprenoid availability to regulation of Th1/Th2 
fate, we have elucidated a mechanism by which AT may suppress Th1-mediated central 
nervous system autoimmune disease.
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Abbreviations used: AT, 
 atorvastatin; CNS, central ner-
vous system; EAE, experimental 
 autoimmune encephalomyelitis; 
ERK, extracellular signal–
 regulated kinase; FTI, farensyl-
transferase inhibitor; GGTI, 
geranylgeranyltransferase inhibi-
tor; HMG-CoA, 3-hydroxy-
3-methylglutaryl–coenzyme A; 
MS, multiple sclerosis; PP, 
 pyrophosphate; Tg, transgenic.
Recently, it was reported that oral administra-
tion of simvastatin (Zocor) reduced the ex-
pected number of new gadolinium-enhancing 
lesions in relapsing-remitting multiple sclerosis 
(MS) patients by 44% in a small 6-mo open-
 label trial (1). The related drug atorvastatin 
(AT) (Lipitor) has also shown promising results 
in lowering disease scores and vascular risk fac-
tors in patients with rheumatoid arthritis (2) 
and is currently being tested in MS in a multi-
center, placebo-controlled trial (http://www.
immunetolerance.org/trials) (3). Studies in 
 experimental autoimmune encephalomyelitis 
(EAE) (4–8) and other animal models of Th1-
mediated disease (9, 10) have revealed that 
statin drugs interfere with the autoimmune de-
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struction of target tissues by inhibiting multiple 
arms of the immune response.
In EAE, statins prevent the production of 
infl ammatory mediators TNF-α, IFN-γ, and 
iNOS by astrocytes and microglia in the central 
nervous system (CNS) (4) and blunt inducible 
expression of MHCII and costimulatory mol-
ecules by these cells (5). These drugs also aff ect 
T cells, the initiators of the autoimmune pro-
cess, by preventing their expansion, Th1 diff er-
entiation, and migration across the blood–brain 
barrier (5–8). When myelin-reactive CD4+ T 
cells are primed with antigen in the presence 
of statins, they instead secrete lower amounts of 
TNF-α and the Th1 cytokine IFN-γ and higher 
amounts of protective Th2 cytokines such as 
IL-4 (5, 6, 8). Adoptive transfer studies have de-
monstrated that AT-generated, myelin-reactive 
Th2 cells have a limited capacity to migrate into 
the CNS  (unpublished data) and provide sustained 
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protection from  further attacks of paralysis (5).  Interestingly, 
a similar bias toward a higher ratio of Th2/Th1 CD4+ cells in 
peripheral blood has been observed in human cardiac patients 
receiving low-dose (20 mg/d) AT therapy (11).
Despite these advances, the molecular mechanism by 
which statins modulate T cell immunity is unknown. This 
is important given the broad clinical administration of these 
agents (25 million people world-wide) (12). Identifi ed 
Figure 1. The mevalonate pathway intermediate farnesyl-PP and 
its alcohol precursor farnesol reverse the Th2 bias promoted by 
atorvastatin. (A) The mevalonate pathway. Metabolites and enzymes in 
the pathway are shown in black, drug inhibitors are shown in red, alcohol 
precursors to metabolites are shown in green, and HMG-CoA reductase 
and pathway end-products are shown in blue. CoQ, coeznyme Q10/ubi-
quinone. (B) Purifi ed naive B10.Pl CD4+ cells stimulated with 5 μg/ml 
αCD3/αCD28 were cultured in the presence or absence of 10 μM atorva-
statin (AT), 100 μM mevalonate, or 5 μM farnesyl-PP. Proliferation (top) 
was measured by [3H]-thymidine incorporation, and IFN-γ (middle) and 
IL-4 (bottom) accumulation in culture supernatants were measured by 
ELISA. These metabolite doses were optimal in reversal of AT effects. 
 Values are mean ± SE of three cultures. Results are representative of 
three independent experiments. *, denotes a signifi cant (P < 0.05) differ-
ence from αCD3/αCD28 stimulation group. (C and D) Female SJL mice 
(n = 10/group) were immunized with PLP p139-151 in CFA and daily 
were fed PBS or AT (10 mg/kg) and/or were injected with farnesol (FOH) 
(5 mg/kg, i.p.). At day 10 after immunization, two spleens were taken 
from representative mice in each group and pooled, and isolated spleno-
cytes were cultured ex vivo with PLP p139-151 peptide. C shows the 
mean ± SE clinical scores of these mice, whereas D shows the prolifera-
tion of [3H] incorporation (left), IFN-γ (middle), and IL-4 (right) produc-
tion by these cells. *, denotes a signifi cant difference from (P < 0.05) 
PBS control.
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 protein targets of these drugs include 3-hydroxy-3-
 methylglutaryl–coenzyme A (HMG-CoA) reductase, a rate-
limiting enzyme in the mevalonate pathway that generates 
cholesterol and isoprenoid derivatives (Fig.1 A) (13, 14) 
and the integrin, leukocyte function antigen-1 (15). In the 
present study, we provide novel evidence that the Th2 bias 
promoted by AT is the result of a reduction of the mevalo-
nate pathway-derived isoprenoids, farnesyl-pyrophosphate 
(PP) and all-trans geranylgeranyl-PP in T cells. These lipid 
derivatives are known to covalently attach to and mediate 
the membrane association of certain signaling proteins and 
metabolites in cells (13, 14). We show that in vivo deple-
tion of these lipids in EAE mice via oral AT administration 
prevented the membrane association of farnesylated Ras 
and geranylgeranylated RhoA, but not other GTPases in 
lymph node cells. This was associated with compromised 
TCR- induced activation of Ras and RhoA eff ectors such 
as extracellular signal–regulated kinase (ERK), p38, and 
their cotarget c-fos. Because c-fos (as part of AP-1) transac-
tivates the IFN-γ promoter and represses the IL-4 pro-
moter (16), our results explain how AT can bias naive 
CD4+ T cells to produce relatively higher amounts of IL-4 
in the early  period of antigen signaling and thus trigger 
the Th2 program of diff erentiation. By connecting specifi c 
 isoprenoids in the mevalonate pathway to T cell receptor 
signaling pathways that regulate cytokine production, we 
have elucidated a mechanism of how statins may inhibit 
Th1-mediated autoimmunity.
RESULTS
AT prevents Th1 differentiation of CD4+ cells by targeting 
HMG-CoA reductase
Previous reports have shown that the eff ect of AT in T cells 
is reversed by mevalonate (5, 6), suggesting that the actions of 
this drug may be mediated through inhibition of HMG-CoA 
reductase (Fig. 1 A). However, because statins are structurally 
similar to mevalonate and have other ligands on immune cells 
(i.e., leukocyte function antigen-1) (15), it is also possible 
that such a reversal is a result of competition between meval-
onate and AT for binding on protein targets other than 
HMG-CoA reductase. We thus tested whether the eff ects of 
AT on T cells could also be reversed by farnesyl-PP, the last 
common intermediate in the mevalonate pathway that has 
a diff erent structure than mevalonate. In response to αCD3/
αCD28 costimulation, purifi ed naive (CD62L+/CD44low) 
CD4+ T cells proliferated and diff erentiated to secrete high 
amounts of the Th1 cytokine IFN-γ (Fig. 1 B). As shown 
previously (5, 6, 8), AT blunted these T cell responses and 
enhanced their production of IL-4 (Fig. 1 B). Farnesyl-PP, 
like mevalonate, fully reversed the eff ects of AT and, when 
administered alone, enhanced the TCR-induced prolifera-
tion of CD4+ cells (Fig. 1 B).
Paralleling these in vitro fi ndings, administration of 
farnesol, a lipophilic, alcohol precursor to farnesyl-PP (17), 
reversed the clinical and immune modulatory eff ects of AT 
in vivo during EAE (Fig. 1, C and D, and Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20051129/
DC1). Interestingly, myelin (PLP p139-151)-reactive cells 
taken from mice treated with farnesol alone also proliferated 
more vigorously and secreted higher amounts of IFN-γ 
ex vivo in response to stimulation with specifi c peptide (Fig. 
1 D). Collectively, these fi ndings confi rm that AT modu-
lates the Th diff erentiation of CD4+ cells by inhibiting the 
production of an intermediate in the mevalonate pathway. 
They also suggest that accumulation of farnesyl-PP in re-
sponse to farnesol treatment may enhance the expansion of 
Th1 eff ector cells.
Figure 2. Oral atorvastatin treatment does not affect circulating 
or T cell cholesterol. (A) B10.PL mice (n = 4/group) were treated with 
either PBS or 10 mg/kg atorvastatin (AT) for 30 d after which time the 
liver was removed and HMG-CoA reductase (HMG-CoAR) transcript lev-
els were assessed using real-time RT-PCR. *, denotes a signifi cant differ-
ence (P < 0.05) from PBS liver. (B) Serum levels of total cholesterol 
(mg/dL) in mice treated orally with PBS or AT (10 mg/kg). Serum was 
taken from mice at 5 d after treatment in the morning after an overnight 
fast. Values are mean ± SE of fi ve mice. (C) T cells were isolated from the 
spleens of mice treated as in B and total cholesterol (μg/mg protein) was 
measured in lipid extracts of these cells using the Amplex Red Choles-
terol Assay. (D) Flow cytometric analysis of fi lipin staining in purifi ed 
T cells taken from mice treated as in B (left) or in T cells that were incu-
bated in vitro in serum-free media for 2 h with the cholesterol-depleting 
agent β-methyl-cyclodextrin (BMCD) (right). The latter experiment served 
as a positive control to demonstrate the sensitivity of this assay to detect 
cholesterol changes.
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Effects of AT on T cell growth and differentiation 
are independent of cholesterol reduction
Cholesterol is a major product of farnesyl-PP (Fig. 1 A). 
 Although it has been reported that depletion of this lipid in 
T cells can attenuate TCR signaling by disruption of choles-
terol-rich lipid rafts (18), a recent in vitro study of malig-
nant T cells showed lipid raft disruption by statins only in 
the complete absence of exogenous cholesterol in the me-
dia (19). We found that in the context of the whole organ-
ism, AT treatment (10 mg/kg) reduced the production of 
this metabolite by the liver as indicated by an elevation in 
the mRNA expression of HMG-CoA reductase (this gene 
is negatively regulated by sterols in this tissue; reference 13) 
(Fig. 2 A). However, the total amount of cholesterol in the 
serum or in T cells was unchanged by this treatment (Fig. 2, 
B and C). The level of membrane-associated cholesterol was 
also not altered in T cells in response to oral administration 
of this drug as assessed via fl ow cytometric analysis of fi lipin 
staining (Fig. 2 D, left). The lack of detectable change in 
membrane cholesterol with AT was not a result of limits in 
the sensitivity of this assay, because decreased fi lipin fl uores-
cence was observed in T cells incubated in serum-free media 
with the cholesterol-depleting agent β-methyl cyclodextrin 
(Fig. 2 D, right).
To more specifi cally address the role of the sterol 
branch of the mevalonate pathway in immunomodulation, 
we examined the eff ects of the squalene synthetase inhibi-
tor Zaragozic Acid A (10 mg/kg) on encephalitogenic T 
cell responses during EAE. At this dose, Zaragozic Acid A 
inhibits liver sterol synthesis (20), reduces circulating cho-
lesterol (Fig. 3 A) and at the same time causes an accumula-
tion of farnesol in mice (20). Daily subcutaneous injection 
of mice with Zaragozic Acid had opposite eff ects to AT 
and caused PLP p139-151–reactive cells to proliferate more 
vigorously (Fig. 3 B) and secrete higher amounts of IFN-γ 
(Fig. 3 C) and lower amounts of IL-4 (Fig. 3 D) compared 
with PBS-injected counterparts. Zaragozic Acid A treat-
ment also exacerbated EAE at several time-points in disease 
(Fig. 3 E and Table S2, available at http://www.jem.org/ 
cgi/content/full/jem.20051129/DC1).
 To examine whether the enhanced proliferation of Th1 
cells triggered by Zaragozic Acid A was a result of enhanced 
fl ux of farnesyl-PP into isoprenoid branches of the pathway, 
we investigated the eff ect of this drug on the de novo incor-
poration [1-3H] farnesyl-PP into T cell proteins in vitro. We 
found that in comparison to media control, Zaragozic Acid A–
treated T cells displayed an increased abundance of tritium-
labeled proteins in the 21–29 kD range, which is compatible 
Figure 3. Specifi c inhibition of the sterol branch of the mevalo-
nate pathway enhances T cell proliferation and Th1 differentiation. 
SJL mice (n = 10/group) were immunized with PLP p139-151 in CFA and 
were injected once daily with either PBS or Zaragozic Acid A (10 mg/kg, 
i.p.). At day 10 after immunization, axillary, brachial, and inguinal lymph 
nodes were taken from representative mice in each group and pooled, 
and isolated cells were cultured ex vivo with PLP p139-151 peptide. 
(A) Total cholesterol (μM) in serum taken at the peak of disease activity. 
Values are mean ± SE of fi ve mice. (B–D) Proliferation of PLP p139-151 
reactive cells (B) was measured by [3H]-thymidine incorporation, and IFN-γ 
(C) and IL-4 (D) accumulation in culture media was measured by ELISA. 
Values are mean ± SE of three cultures. (E) Mean ± SE clinical scores of 
mice in the various groups over the time-course of disease are shown. 
*, denotes a difference (P < 0.05) from PBS control. (F) De novo incorpo-
ration of [1-3H]-farnesyl-PP into cellular proteins in the absence or pres-
ence of Zaragozic Acid A (200 μM) in T cell cultures. The protein marker is 
in lane 3 (top). Gels were stained with Coomassie blue to ensure that 
equivalent amounts of each protein sample were loaded.
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with the size of small G proteins (Fig. 3 F).  Collectively, these 
results suggest that the major eff ects of AT on Th1 diff eren-
tiation and clinical disease are cholesterol independent and 
instead the result of reductions in isoprenoid biosynthesis.
AT inhibits T cell growth and Th1 differentiation 
by preventing protein isoprenylation
Farnesyl-PP serves as a metabolic precursor to a variety of 
isoprenoid derivatives such as decaprenyl-PP (isoprenoid 
moiety of ubiquinone), 2-cis-geranylgeranyl-PP (important 
for N-glycoprotein synthesis), and all-trans geranylgeranyl-
PP (13, 14) (Fig. 1 A). The latter isoprenoid along with 
 farnesyl-PP are, respectively, attached to the COOH termi-
nus of certain signaling proteins via the action of geranylger-
anyl transferases and farnesyltransferase (21). These isoprenoid 
modifi cations mediate the membrane association of many 
GTPases (21). We thus tested whether specifi c isoprenoid 
derivatives could reverse the eff ects of AT on T cells cultured 
with specifi c peptide. Splenocytes from MBP Ac1-11 TCR 
transgenic (Tg) mice were used as a source of T cells for 
these assays.
Of all the metabolites tested, only all-trans  geranylgeranyl-
PP, the isoprenoid moiety of geranylgeranylated proteins, 
and its precursor, farnesyl-PP, restored the antigen-driven 
Figure 4. Prenylated proteins have a regulatory function in T cell 
growth and differentiation. (A and B) Splenocytes taken from MBP 
Ac1-11 TCR Tg mice were stimulated with 5 μg/ml Ac1-11 peptide in the 
presence or absence of 10 μM atorvastatin (AT), 5 μM farnesyl-PP (FPP), 
5 μM all-trans geranylgeranyl-PP (all-trans GGPP), 1 μM 2-cis geranyl-
geraniol (2-cis GGOH), or 1 μM ubiquinone (all in A) or DMSO vehicle, 
5 μM of the farnesyltransferase inhibitor FTI-277 or 5 μM of the geranyl-
geranyltransferase-I inhibitor GGTI-298 (all in B). Proliferation (top) was 
measured by [3H]-thymidine incorporation, and IFN-γ (middle), and IL-4 
(bottom) accumulation in culture supernatants was measured via ELISA. 
These results are representative of data from at least three independent 
experiments. *, denotes a difference (P < 0.05) from peptide stimulation 
alone. Note that the additive effects of FTI and GGTI were not examined in 
these experiments because this drug combination compromised T cell 
viability (not depicted). Values are mean ± SE of triplicate cultures. 
(C) 5 μM farnesyl-PP is effective at restoring the prenylation of Ras, 
a representative farnesylated protein and 5 μM all-trans GGPP is effective 
at restoring the prenylation of Rap, a representative geranylgeranylated 
protein. Because the carboxy-termini of these proteins are cleaved upon 
prenylation, posttranslationally modifi ed forms (single arrows) of these 
proteins can be distinguished from their unprenylated forms (double 
 arrows) via altered mobility on Western blots of SDS-PAGE gels (reference 27). 
(D) 1 and 5 μM of FTI-277 and 5 μM GGTI-298, respectively, inhibit Ras 
farnesylation and Rap1 geranylgeranylation. (E) Protein samples from 
cells treated with FTI, GGTI, or vehicle control (as in B) were subjected to 
Western blot analysis of T-bet and GATA-3 expression.
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proliferation of AT-treated T cells and reversed the Th2 bias 
promoted by this drug (Fig.4 A). The doses of farnesyl-PP 
and geranylgeranyl-PP used in these assays were eff ective at 
restoring the prenylation of protein targets (Fig. 4 C). We 
also tested the eff ects of these isoprenoids in AT-treated T cells 
stimulated with α-CD3 and α-CD28 (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20051129/DC1) 
and found that both farnesyl-PP and geranylgeranyl-PP con-
tributed to the reversal of AT eff ects on T cell proliferation 
and Th1 diff erentiation. Collectively, these data strongly 
 suggest that AT modulates Th diff erentiation by inhibiting 
isoprenoid production in T cells.
To confi rm the involvement of isoprenylated proteins in 
T cell growth and Th1 diff erentiation, we investigated the 
eff ects of inhibitors of farnesyltransferase (FTI-277) and gera-
nylgeranyltransferase-I (GGTI-298) on antigen-driven T cell 
responses (Fig. 4, B and D). Treatment of MBP Ac1-11 TCR 
Tg T cells with an eff ective dose (Fig. 4 D) of the geranyl-
geranyltransferase inhibitor (GGTI) signifi cantly inhibited 
T cell proliferation (Fig. 4 B). However, the growth of these 
cells was not altered by treatment with the farnesyltransferase 
inhibitor (FTI) (Fig. 4 B). Consistent with the prominent in-
volvement of protein farnesylation in regulating Th1 diff er-
entiation, FTI-277 inhibited the production of IFN-γ and 
induced a subtle increase in IL-4 by T cells (Fig. 4 B). In par-
allel, this drug decreased T-bet protein and caused a subtle 
increase in GATA-3 expression (Fig. 4 E). GGTI-298, 
though not infl uencing IFN-γ secretion or T-bet expression, 
induced low-level IL-4 production and a subtle increase in 
GATA-3 expression (Fig. 4, B and E). Similar eff ects of 
FTI-277 and GGTI-298-treatment on T proliferation and 
cytokine production were observed in cultures of purifi ed T 
cells stimulated with anti-CD3 and anti-CD28 (Fig. S1). 
Note that in both of these T cell assays, the amount of IL-4 
triggered by each of these prenyltransferase inhibitors did not 
approach the level induced by AT (Fig. 4 B and Fig. S1), sug-
gesting that geranylgeranylated proteins cooperate with 
farnesylated proteins to fully repress the production of this 
Th2 cytokine in T cells in response to antigen signals. Col-
lectively, these results suggest that AT prevents T cell prolif-
eration and Th1 diff erentiation by inhibiting the biosynthesis 
of farnesyl-PP and all-trans geranylgeranyl-PP, leading to 
 reduced prenylation of protein targets.
Oral AT administration promotes a Th2 bias by decreasing 
the membrane association of Ras and RhoA
Farnesylated Ras and geranylgeranylated Rac1, RhoA, and 
Rap are the only prenylated proteins known to be situated 
in antigen-activated signaling pathways that modulate T 
helper diff erentiation (22). Though numerous in vitro stud-
ies of malignant cells have demonstrated an inhibitory eff ect 
of high-dose (10–50 μM) statin treatment on the prenylation 
and membrane-association of Ras and Rho GTPases (e.g., 
19, 23, 24), a similar in vivo eff ect of statins on these proteins 
has not been reported. We thus investigated whether oral 
AT administration altered the subcellular localization of Ras, 
RhoA, Rac1, or Rap in T cells in vivo during EAE. We used 
draining lymph nodes from EAE mice as a source of enriched 
T cells. We found that AT treatment induced an accumula-
tion of Ras, Rap, and RhoA, but not Rac1 in the cytosol of 
draining lymph node cells (Fig. 5 A). This was accompanied 
by a prominent decrease in Ras and RhoA at the membrane 
(Fig. 5 A). This eff ect of AT on Ras and Rho was reversed 
by coadministering farnesol to mice (Fig. S2 A, available at 
http://www.jem.org/cgi/content/full/jem.20051129/DC1). 
Time-course experiments demonstrated that the alteration 
in Ras and RhoA localization in immune cells by AT was 
transient (Fig. 5 B) and occurred as early as 6 h (not depicted) 
and as late as 20 h (Fig. 5 B) after oral treatment. Because 
membrane localization is requisite to the functioning of these 
proteins, our fi ndings strongly implicate Ras and RhoA as 
the major targets of AT in immune modulation.
It has been suggested that early cytokine production by 
naive CD4+ cells in response to antigen stimulation may be 
infl uenced by the extent of activation of the Ras–ERK sig-
naling pathway downstream of the TCR (16, 25). In response 
to strong TCR signals, Ras and ERK are activated in a sus-
tained fashion leading to increased c-fos activity (16, 25). 
c-fos (together with jun proteins such as AP-1) transactivates 
the IFN-γ promoter and may repress the IL-4 promoter (16) 
(Fig. 6 A). Decreased RhoA activation may also tip cytokine 
balance toward Th2 via inhibition of p38, a kinase that posi-
tively regulates IFN-γ production (26) (Fig. 6 A). We thus 
Figure 5. Oral atorvastatin treatment decreases the membrane 
association of Ras and RhoA GTPases. (A) Lymph node cells were taken 
from fi ve (SJL×PLJ)F1 mice that had been immunized 10 d previously with 
MBP Ac1-11 in CFA. These mice had been fed daily with either PBS or AT 
(10 mg/kg). At 16 h after the last dosing, lymph nodes were taken from 
mice and pooled, and the soluble and membrane fractions of these cells 
were separated by ultracentrifugation (100,000 g). Proteins were sub-
jected to SDS-PAGE electrophoresis and Western blot analysis of Ras, 
RhoA, Rap, Rac1, and β-actin was performed. (B) B10.Pl mice (n = 2/
group) were fed with AT (10 mg/kg) once daily for 3 d. After the third 
treatment, spleens were taken from mice at different time points. Spleno-
cytes were isolated, the soluble and membrane fractions were obtained, 
and Western blot analysis of Ras, RhoA, and Rac1 expression was 
 performed as in A.
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tested whether AT treatment compromised the TCR-
 induced activation of ERK and p38 kinases in lymph nodes 
during EAE. Consistent with eff ects on Ras and RhoA, 
in vivo AT treatment blunted the TCR-induced activation 
of ERK and p38 as well as decreased the DNA-binding of c-fos 
(a target of ERK and p38) and ATF-2 (a target of p38 and 
JNK) (Fig. 6, C and D). This eff ect of AT treatment on T cell 
ERK and p38 phosphorylation was reversed by cotreatment 
of mice with farnesol (Fig. S2 B). Consistent with the lack of 
a major eff ect of AT on the subcellular localization of Rac1, 
this drug did not modulate JNK phosphorylation nor the ac-
tivity of its primary target, c-jun (Fig. 6, C and D). Oral AT 
treatment also did not inhibit other signaling events triggered 
by anti-CD3 or anti-CD28 cross-linking including IκB deg-
radation (Fig. 6 C), Zap-70 phosphorylation (Fig. 6 E), and 
calcium fl ux (Fig. 6 F).
To test the hypothesis that this inhibition of Ras-ERK 
and RhoA-p38 signaling by AT was responsible for the Th2 
bias induced by this drug, we explored the eff ects of specifi c 
inhibitors of MEK (PD98059), an upstream eff ector of ERK, 
and p38 (SB203580) on the antigen-driven diff erentiation of 
naive CD4+ cells. Exposure of CD4+ cells to 10 μM of the 
MEK inhibitor (a dose that does not aff ect the proliferation or 
viability of T cells; unpublished data) decreased the produc-
tion of IFN-γ and increased the secretion of IL-4 by these 
cells in response to specifi c peptide (Fig. 7 A). This concentra-
tion of PD98059 also reduced the phosphorylation of ERK 
(Fig. 7 A, bottom). Similarly, exposure of T cells to the p38 
kinase inhibitor at doses that inhibit p38 phosphorylation (Fig. 
7 B, bottom) and activity (26) induced IL-4 production (only 
at 0.1 μM) and inhibited IFN-γ production by these cells 
(Fig. 7 B). The p38 kinase inhibitor also had a more profound 
eff ect than the MEK inhibitor in inhibiting T cell prolifera-
tion through higher doses tested (10–100 μM) (unpublished 
data). Collectively, these data support the hypothesis that 
Ras-ERK and RhoA-p38 signaling pathways are the targets 
of AT in Th2 diff erentiation and inhibition of T cell growth.
In vivo treatment with an FTI prevents Th1 differentiation 
during EAE
In light of the more prominent involvement of protein farnesyl-
ation and ERK signaling in regulating the Th1 diff erentiation of 
Figure 6. Oral atorvastatin treatment inhibits ERK and p38 sig-
naling pathways in T cells. (A and B) Cartoon summarizing the location 
of prenylated proteins (in green) in signaling pathways downstream of 
TCR stimulation and the transcription factors that act at IFN-γ and IL-4 
promoters in PBS- (A) and AT-dosed (B) mice. Not all pathway intermedi-
ates are shown. (C–E) Lymph node cells (C and D) or purifi ed CD4+ cells 
(E) taken from mice treated as in Fig. 5 were cultured (2 × 106/ml) with 
5 μg/ml αCD3 and 5 μg/ml αCD28 antibodies for various durations. 
(C) Western blot analysis of phospho-ERK, ERK, phospho-JNK, JNK, 
 phospho-p38, p38 MAPK, and IκB using whole cell lysates prepared from 
these cells. (D) shows results of an ELISA-based DNA binding assay of 
c-fos, ATF-2, and c-jun using nuclear extracts prepared from parallel 
 cultures that were stimulated with 5 μg/ml αCD3/αCD28 antibodies for 
10 h. (E) Western blot analysis of phospho-Zap 70 and Zap 70 in lysates 
of these cells. (F) FACS analysis of calcium fl ux in CD4+ T cells in response 
to anti-CD3 cross-linking. The arrow denotes the time when the stimulus 
was added to cells.
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MBP-reactive cells in vitro and reports that FTIs (but not 
GGTIs) are well tolerated in mice (27), we investigated the 
clinical benefi ts of the FTI, L-744,832 (30 mg/kg) on the de-
velopment of EAE (Fig. 8, A–D). We administered the maxi-
mum tolerated dose of this drug, which is reported to cause 
regression of Ras-related tumors in mice (28). Similar to in vitro 
fi ndings using FTI-277 (Fig. 4 B), IFN-γ production by PLP 
p139-151–reactive cells from L-744,832–treated mice was 
markedly reduced compared with control counterparts (Fig. 8 
C). Despite this, FTI-treated mice still developed EAE, albeit 
the day of onset of clinical symptoms for grade one or higher 
(12.7 ± 0.6 in FTI vs. 11.3 ± 0.6 in vehicle, P < 0.01) and or 
grade two or higher (19.4 ± 2.0 in FTI vs. 16.0 ± 1.8 in ve-
hicle, P < 0.01) was signifi cantly delayed compared with ve-
hicle controls (Fig. 8 A). The development of infl ammation in 
FTI-treated mice may relate to the fact that this drug caused 
PLP p139-151–reactive cells to secrete higher amounts of IL-2 
(Fig. 8 B), yet did not promote IL-4 secretion (not depicted) 
nor dampen the production of the proinfl ammatory cytokine 
TNF-α by these cells (Fig. 8 D). Collectively, these results 
suggest that dual inhibition of protein farnesylation and gera-
nylgeranylation is required to fully promote a Th2 bias of 
CD4+ cells and prevent the development of CNS infl amma-
tion during EAE.
D I S C U S S I O N 
Several studies have demonstrated that in vivo statin treatment 
can cause a protective Th2 bias in animal models of Th1-
mediated autoimmune disease (for review see reference 3). 
These fi ndings have created considerable enthusiasm for test-
ing these agents in patients with MS and rheumatoid arthritis 
(1, 2). The purpose of the present study was to defi ne the 
mechanism of immune modulation by this drug. Here, we 
show that the eff ect of AT in causing a Th2 bias is the result 
of a reduction in the biosynthesis of isoprenoids that serve 
as membrane attachments for Ras and RhoA. Farnesyl-PP, 
which mediates Ras farnesylation, restored IFN-γ  production 
by AT-treated myelin-reactive T cells, whereas all-trans-
geranylgeranyl-PP, the precursor to RhoA geranylgera-
nylation, reversed the AT block in T cell proliferation and 
Figure 7. MEK and p38 inhibitors induce Th2 bias of naive CD4+ 
cells. Naive CD4+ T cells were isolated from spleens of MBP Ac1-11 TCR 
Tg mice and were cultured with specifi c peptide in the presence or ab-
sence of 5 μg/ml MBP Ac1-11, 1, or 10 μM of the MEK inhibitor PD98059 
(A) or 0.1–1 μM of the p38 inhibitor SB203580 (B). Note that these par-
ticular doses of MEK or p38 inhibitors did not affect the proliferation or 
viability of T cells (data not depicted), but did inhibit the phosphorylation 
of ERK and p38 (bottom). *, denotes a signifi cant (P < 0.05) difference 
from MBP Ac1-11 stimulated group. β-actin served as a loading control. 
Values are mean ± SE of triplicate cultures.
Figure 8. In vivo administration of the FTI L-744,832 inhibits Th1 
differentiation. Female SJL mice were immunized with PLP p139-151 in 
CFA and daily were injected s.c. with either vehicle or L-744,832 (30 mg/kg). 
At day 10 after immunization, spleens were taken from representative 
mice in each group and isolated splenocytes were cultured ex vivo with 
PLP p139-151 peptide. (A) The mean ± SE clinical scores of these mice. 
(B–D) PLP p139-151-stimulated production of IL-2 (B), IFN-γ (C), and 
TNF-α (D) by isolated splenocytes. Values are mean ± SE of triplicate 
cultures. *, denotes a signifi cant difference from vehicle control.
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 coordinated with farnesyl-PP to fully reverse the increase in 
IL-4 promoted by this drug. We also show for the fi rst-time 
that oral dosing with AT compromised the membrane asso-
ciation of Ras and RhoA GTPases and the TCR-induced 
activation of targets ERK and p38 in T cells. Inactivation of 
ERK and p38 signaling mimicked the eff ects of AT, strongly 
implicating Ras-ERK and RhoA-p38 pathways as the targets 
of this drug. Thus, by linking isoprenoid intermediates to 
two arms of the TCR signaling cascade that modulate T 
cell cytokine production, we have elucidated a mechanism 
of how statins may cause a Th2 bias in vivo during EAE.
Our fi nding that oral dosing with AT caused Ras, RhoA, 
and Rap GTPases to be preferentially diverted to the cytosol 
instead of the membrane of lymph node cells in vivo is the 
fi rst demonstration of its kind. These results thus expand 
upon previous in vitro reports of lovastatin in tumor cell lines 
(19, 23, 24) as well as lend concrete support to the prevailing 
notion that the pleiotrophic eff ects of statins in treating ath-
erosclerosis and cancer in animal models are the result of re-
ductions in isoprenoid biosynthesis (29–32). Though oral AT 
administration signifi cantly depleted Ras and RhoA at the 
membrane of lymph node cells, in comparison, Rap or Rac1 
were only marginally aff ected. The reason for this diff erence 
is unclear, but may relate to variations in the half-lives of 
these proteins (24). Nonetheless, because membrane-associa-
tion is necessary for the functioning of GTPases, we conclude 
that Ras and RhoA are the major targets of statin in immune 
modulation in vivo.
Previous reports have demonstrated that the strength of 
ERK activation in response to TCR stimulation may infl u-
ence cytokine production and alter the course of T helper 
diff erentiation by altering the binding of c-fos to AP-1 con-
sensus elements (16). Peptides that bind the TCR with strong 
avidity induce Th1 diff erentiation of CD4+ cells and cause 
a sustained activation of Ras and ERK that triggers c-fos ac-
tivity (16, 25). c-fos (with jun as AP-1) appears to repress the 
IL-4 promoter (16) and coordinates with other transcription 
factors such as ATF-2 and NFAT to mediate the transactiva-
tion of the IFN-γ promoter (26) (Fig. 6 A). However, under 
conditions when ERK activity is low, such as in the presence 
of a weak-binding altered peptide ligand (16), or weakened 
Ras (33), or MEK signaling (16, 34), IFN-γ production is 
minimal and IL-4 is induced. In this regard, our fi ndings that 
AT decreased the DNA binding of c-fos and inhibited the 
activation or Ras-ERK and RhoA-p38 signaling pathways 
that target this transcription factor provide a mechanistic ex-
planation for the Th2 bias promoted by statins. Interference 
of p38 activity by AT may have also contributed to this Th2 
deviation by reducing the activity of ATF-2 at the IFN-γ 
promoter (26). In light of this evidence, we propose a model 
for AT action on T cells in vivo (Fig. 6, compare A and B), 
whereby this drug selectively inhibits the membrane associa-
tion of Ras and RhoA leading to decreased activation of ERK 
and p38 signaling pathways that target AP-1 and ATF-2.
Despite the established role for Ras and ERK in the reg-
ulation of IFN-γ production (in this paper and references 
16, 33, 34), in vivo FTI treatment only delayed the onset of 
EAE. These fi ndings emphasize the involvement of geranyl-
geranylated proteins in mediating the development of CNS 
infl ammation. Indeed, our data indicate a role for geranyl-
geranylated Rho proteins in mediating the proliferation of 
encephalitogenic T cells. These results thus correspond with 
previous reports that statins cause G1 arrest (35) and that 
geranylgeranylated proteins regulate the G1 to S transition 
(36). We also found that inhibition of protein geranylgera-
nylation in myelin-reactive cells was requisite for full induc-
tion of IL-4 and was likely required for the attenuation of 
TNF-α production by AT (i.e., AT [reference 5], but not 
FTI treatment diminishes T cell production of this cyto-
kine). These fi ndings, coupled with the established involve-
ment of geranylgeranylated Rho proteins in regulating 
the transmigration of T cells across brain endothelium (7), 
emphasize that dual inhibition of farnesylation and geranyl-
geranylation by statins is necessary to prevent the develop-
ment of CNS autoimmunity.
Although reducing the production of farnesyl-PP by AT 
hindered T cell growth and Th1 diff erentiation, in vivo treat-
ments that cause increased incorporation of this metabolite 
into prenylated proteins, such as farnesol (17) or Zaragozic 
Acid A (18, 37), induced pathogenic myelin-reactive T cells 
to proliferate more vigorously, secrete higher amounts of 
IFN-γ, and precipitate worse EAE. Thus, accumulation of 
farnesyl-PP may enhance Th1-mediated infl ammation in 
vivo. Though we observed in vitro Zaragozic Acid A treat-
ment to trigger an increased accumulation of farnesyl-PP in 
T cells, it remains unclear whether this also occurred in mice 
in response to in vivo treatment or whether it was the in-
creased liver production of farnesyl-PP–derived lipids (18, 
37) that was responsible for the immune modulatory eff ects 
of this drug. The latter possibility (i.e., that the liver produc-
tion of isoprenoids can boost adaptive immune responses) is 
provocative and provides an interesting correlate to reports 
that metabolic precursors in the mevalonate pathway are 
preferentially diverted toward isoprenoid as opposed to sterol 
biosynthesis in the liver during the acute phase response to 
infl ammatory stimuli (38, 39).
In conclusion, we show that farnesylated Ras and gera-
nylgeranylated RhoA proteins are the targets of AT in im-
mune modulation in vivo. Our results also underscore that 
inhibition of both protein farnesylation and geranylgeranyl-
ation in T cells is key to promoting a Th2 bias and preventing 
the development of EAE. Because oral AT administration is 
well tolerated, whereas continuous and combined FTI and 
GGTI therapy is toxic in vivo (27), we maintain that of these, 
statin treatment is a more promising approach than selective 
inhibition of individual prenyltransferases for treatment of 
MS and other Th1-mediated autoimmune diseases.
MATERIALS AND METHODS
Reagents. Mevalonate, farnesol, farnesyl-PP, all-trans geranylgeranyl-PP, 
ubiquinone, Zaragozic Acid A, β-methyl cyclodextrin, and fi lipin were ob-
tained from Sigma-Aldrich. Cold 2-cis geranylgeraniol, [acetyl-3H] acetyl 
CoA (20 Ci/mmol), and [1-3H] farnesyl-PP (60 Ci/mmol) were obtained 
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from American Radiochemicals. Purifi ed AT was a gift from R. Laskey 
(Pfi zer, New York, NY). FTI-277, GGTI-298, L-744,832, SB203580, 
and PD98059 were obtained from Calbiochem. Fluo-4 was obtained 
from Invitrogen. Peptides encoding myelin basic protein (MBP), Ac1–11 
(Ac-A S Q K R P S Q R H G ), or proteolipid protein (PLP) p139–151 (H C L G K-
W L G H P D K F ) were synthesized by the Stanford Pan Facility and purifi ed by 
HPLC. Pan Ras (clone 18) and Rac1 (clone 102) antibodies were obtained 
from BD Transduction Labs. RhoA (clone 26C4), Rap1 (clone sc-65), 
T-bet (clone sc-21749), and GATA-3 (clone sc-268) antibodies were obtained 
from Santa Cruz Biotechnology, Inc. Phospho(p42/44)-ERK (no. 9101S), 
p42/p44 MAPK (no. 9102), phospho-JNK (no. 9251S), JNK (no. 9252), 
phospho-p38 (no. 9216S), p38 (no. 9212), phospho-Zap-70 (no. 2701), 
and IκBα (no. 9242) antibodies were all obtained from Cell Signaling. The 
pan-Zap-70 antibody (clone 1E7.2) was obtained from Upstate Biotechnol-
ogy. Goat anti–mouse IgG antibody was obtained from Jackson Immuno-
Research Laboratories.
Mice. Female SJL/J and (PL/J × SJ/L)F1 mice (6–10 wk old) were pur-
chased from The Jackson Laboratory. MBP Ac1-11 TCR Tg mice back-
crossed onto the B10.PL background (40) were maintained in our animal 
facility. All animal protocols were approved by the Division of Comparative 
Medicine at Stanford University and the Committee of Animal Research at 
the University of California San Francisco and animals were maintained in 
accordance with the guidelines of the National Institutes of Health.
EAE induction. EAE was induced in SJL/J mice via subcutaneous immu-
nization with 100 μg PLP p139-151 in an emulsion (volume ratio 1:1) with 
CFA containing 4 mg/ml of heat-killed Mycobacterium tuberculosis H37Ra 
(Difco Laboratories). (PL/J × SJ/L)F1 mice were immunized with MBP 
Ac1-11 in CFA. Mice (n = 10 per treatment group) were examined daily for 
clinical signs of EAE and were scored as followed: 0 = no clinical disease, 
1 = limp tail, 2 = hindlimb weakness, 3 = complete hindlimb paralysis, 4 = 
hindlimb paralysis plus some forelimb paralysis, and 5 = moribund or dead.
In vivo drug treatments. AT (prescription formulation; Pfi zer) was 
brought into suspension in PBS (0.4 mg/ml) and a 0.5-ml volume of this 
suspension (equivalent to 10 mg/kg) was administered to mice orally, once 
daily, using 20-mm feeding needles (Popper and Sons, Inc). Farnesol (undi-
luted lipid, 5 mg/kg) and Zaragozic Acid A (dissolved in saline, 10 mg/kg) 
were injected i.p. once daily. The specifi c inhibitor of farnesyltransferase, 
L-744,832, was dissolved in 0.9% saline (pH 5.4, 30 mg/kg) and injected 
subcutaneously, once daily. Mice treated with appropriate vehicles served as 
controls. All treatments were initiated at 2 d before immunization, and sple-
nocyte and lymph node cells were harvested from representative mice in 
each group at 10 d after disease induction.
Proliferation assays and cytokine analysis. Splenocytes (0.5 × 106 cells/
well), lymph node cells (0.5 × 106 cells/well), or CD4+ T cells (5 × 104 
cells/well) purifi ed by negative selection (columns from R&D Systems) were 
cultured in fl at-bottomed, 96-well plates with appropriate peptide (1–25 μg/ml) 
and irradiated splenocytes (in the case of purifi ed CD4+ cells) or were 
 stimulated with 2 or 5 μg/ml each of αCD3 (clone 145-2C11; BD Biosci-
ences) and αCD28 (clone 37.51; BD Biosciences). Culture medium consisted 
of RPMI 1640 supplemented with l-glutamine (2 mM), sodium pyruvate 
(1 mM), nonessential amino acids (0.1 mM), penicillin (100 U/ml), strepto-
mycin (0.1 mg/ml), 2-mercaptoethanol (5 × 10−5 M), and 10% fetal calf serum. 
After 48–72 h, cultures were pulsed with [3H]thymidine (1 μCi/well) and 
18 h later were harvested onto fi lter paper. The cpm of incorporated 
[3H]thymidine were read using a β-counter. Cytokines were measured in the 
supernatants of cultured cells using anti–mouse OPTEIA ELISA kits (BD 
Biosciences). Supernatants were taken at the time of peak production for each 
cytokine: IL-2 (48 h), IFN-γ (72 h), TNF-α (72 h), and IL-4 (120 h).
Analysis of HMG-CoA reductase mRNA expression via real-time 
RT-PCR. Total RNA was isolated from liver using the Absolutely RNA 
RT-PCR Miniprep kit (Statagene). 1 μg of RNA was reverse-transcribed 
and HMG-CoA reductase and β actin cDNAs amplifi ed according to previ-
ous methods (41) using a Lightcycler (Roche). Primer sequences were as 
follows: HMG-CoA reductase (sense): 5′-T T C T G G C A G T C A G T G G G -3′; 
HMG-CoA reductase (antisense): 5-C A A T G T T T G C T G C G T G G -3′; β-actin 
(sense): 5′-G A A C C C T A A G G C C A A C G C T -3′; and β-actin (antisense): 
5′-C A C G C A C G A T T T C C C T C T C -3′.
T cell cholesterol extraction and amplex red assay. Total cholesterol 
was extracted from cells using the Heider and Boyett method (42). In brief, 
purifi ed cells (10 × 106) were suspended in 500 μl of isopropanol and soni-
cated for 15 s using a microprobe. Samples were centrifuged at 800 g for 
15 min to precipitate cellular proteins. The supernatant containing the cho-
lesterol was decanted to a clean tube, evaporated to dryness, and resuspended 
in 1× reaction buff er. The remaining protein pellet was suspended in 100 μl 
of 0.1 M sodium hydroxide and used for protein determination. Total cho-
lesterol was measured in the lipid extract and in serum of mice using Amplex 
Red Cholesterol Assay kit (Invitrogen).
FACS analysis of fi lipin staining. Membrane-associated cholesterol was 
determined in T cells by measuring fi lipin fl uorescence (43). T cells (106) 
were fi rst fi xed in 120 μl of 4% paraformaldehyde at room temperature for 
12 min, washed three times in 1× PBS, and incubated with the dye (1:100 
of 25 mg/ml fi lipin stock) for 1 h at 4°C. Samples were washed three times 
with 1× PBS and fi lipin fl uorescence was measured using a FACS Vantage 
SE/Diva (BD Biosciences) with the krypton ion laser tuned to UV (350.7–
356.4 nm) and emission detection at 420–460 nm. Data were analyzed using 
FloJo software (Ver. 6.3.3) (Treestar).
Metabolic labeling. De novo incorporation of farnesyl-PP into T cell pro-
teins was assessed using a modifi ed procedure of Corsini et al. (44). In brief, 
purifi ed T cells (3 × 106/ml in stimulation media) were cultured in six-well 
plates coated with anti-CD3 (5 μg/ml) and anti-CD28 (5 μg/ml) in the 
 absence or presence of 200 μM Zaragozic Acid A. After 12 h, T cells were 
pulsed with [1-3H] farnesyl-PP (60 Ci/mmol) and cultured for additional 
20 h. For each condition, cells were pooled and washed three times in 1× PBS 
(containing 1 mM PMSF). After the fi nal centrifuge (1,200 revolutions/min 
for 5 min), cells were resuspended in 1× PBS and sonicated for 15 s using 
a microprobe. Cellular proteins were delipidated (44), 60 μg of protein was 
subjected to SDS-PAGE, and gels were stained with Coomassie blue to 
 visualize proteins. Gels were then treated with Amplify for 30 min, washed, 
dried, and exposed to a Tritium K-Screen (Kodak) for 3 wk. Exposure of the 
screen was detected using a Fx Pro-Plus Molecular Imager and Quantity 
One software (both obtained from Bio-Rad Laboratories).
Cell fractionation and protein isolation. For extraction of total cell pro-
tein, splenocytes or lymph node cells were dissociated from surrounding 
connective tissue, red blood cells were lysed, and cells were counted and re-
suspended in an appropriate volume (10 μl/million cells) of NP-40 buff er 
(150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
Na2PO4, 1 mM glycerol phosphate, 1 mM Na3V04, 1 g/ml leupeptin, 1 mM 
PMSF, Roche protease inhibitor tablet, 20 mM Tris, pH 7.5). After a 30-min 
extraction on ice, samples were centrifuged at 15,000 g for 15 min at 4°C to 
obtain a clarifi ed supernatant. For cell fractionation studies, splenocyte or 
lymph node cells were homogenized in lysis buff er (1 mM EDTA, 20 mM 
Tris-HCl, pH 7.4) using a glass homogenizer and were centrifuged at 
100,000 g using a Beckman ultracentrifuge. The supernatant (soluble frac-
tion) was concentrated using a 10 K molecular limit Nanosep centrifugal 
 device (Pall Life Sciences). The membrane pellet was solubilized in 1× 
 immunoprecipitation buff er (0.15 M NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, and 0.1% SDS, 10 mM Tris-HCl, pH 7.5) and centrifuged at 
15,000 g to obtain a clarifi ed supernatant. Proteinase inhibitors were in-
cluded in all buff ers. Nuclear extracts from lymph nodes cells were isolated 
using the BD Transfactor Extraction Kit (CLONTECH Laboratories, Inc.) 
according to kit directions. The concentration of proteins in each sample 
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was determined using a BCA assay kit (Pierce Chemical Co.). DNA binding 
assays were conducted using a commercial ELISA kit (CLONTECH 
 Laboratories, Inc.).
SDS-PAGE and Western analysis. Each protein sample was suspended in 
2 vol. of 2× SDS Sample Buff er (Bio-Rad Laboratories) and subjected to 
SDS-PAGE electrophoresis using precast Tris-HCl Ready-Gels (Bio-Rad 
Laboratories). Proteins were transferred to PVDF membranes (GE Health-
care) and immunoblotting was performed using conventional methods 
(Santa Cruz Biotechnology, Inc.).
Calcium fl ux analysis. Calcium fl ux in CD4+ T cells was measured after 
CD3 cross-linking using a FACScan (BD Biosciences) (45). In brief, CD4+ 
cells purifi ed from spleens of mice (106/ml), were washed in 1× PBS and 
loaded with Fluo-4 (2 μM) in the presence of CaCl2 (2 mM) for 20 min at 
room temperature. Cells were washed twice with 1× PBS, resuspended at 
a concentration of 2 × 106/ml in FACS buff er, and placed in a 37°C water 
bath. Samples (37°C) were fi rst acquired for 30 s to establish baseline fl uores-
cence in FL1 channel before the addition of anti-CD3 (5 μg/ml) and the 
goat anti–mouse IgG (10 μg/ml). After stimulation, events were collected 
for an additional 10 min. Data were analyzed using the kinetics platform in 
FloJo software (Ver. 6.3.3).
Statistical analysis. Data are presented as means ± SE. When data were 
parametric, a one-way analysis of variance and a Scheff é post-hoc test (for 
>2 groups) or a Student’s t test (n = 2 groups) were used to detect between-
group diff erences. When data were nonparametric, ranks were compared 
amongst groups using a Kruskal-Wallis test and nonparametric test for mul-
tiple comparisons (for >2 groups) or a Mann-Whitney U test (n = 2 groups). 
A value of P < 0.05 was considered signifi cant.
Online supplemental material. Fig. S1 shows the infl uence of AT and 
isoprenoid metabolites on the proliferation of and cytokine production by 
purifi ed T cells in culture. Fig. S2 shows how in vivo treatment with farnesol 
can reverse the eff ects of AT on the membrane localization of Ras and 
RhoA and the TCR-induced phosphorylation of ERK and p38 in lymph 
node cells. Tables S1 and S2 summarize the clinical features of EAE in ex-
periments depicted in Figs. 1 and 3. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20051129/DC1.
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